García Rodríguez L A, González-Pérez A
Centro Español de Investigación Farmacoepidemiológica (CEIFE), C/Almirante 28 2, 28004 Madrid, Spain.
Br J Cancer. 2004 Aug 2;91(3):525-9. doi: 10.1038/sj.bjc.6602003.
We conducted a cohort study with a nested case-control analysis to evaluate the effect of anti-inflammatory drugs in breast cancer incidence using the General Practice Research Database. Women taking aspirin and paracetamol for 1 year or longer had an odds ratio (OR) of 0.77 (95 percent confidence interval (95% CI): 0.62,0.95) and 0.76 (95% CI: 0.65,0.88), respectively, compared to nonusers. Daily doses of aspirin (75 mg) and paracetamol (up to 2000 mg) showed the greatest reduced risk. Use of non-aspirin nonsteroidal anti-inflammatory drugs for more than 1 year was not associated with a reduced risk of breast cancer (OR=1.00 (95% CI: 0.84, 1.17), and the corresponding estimate among users with at least 2 years duration was similar. Our findings suggest that aspirin at cardioprophylactic doses as well as paracetamol at analgesic doses is associated with a reduced risk of breast cancer.
我们进行了一项队列研究,并采用巢式病例对照分析,利用全科医疗研究数据库评估抗炎药物对乳腺癌发病率的影响。与未使用者相比,服用阿司匹林和扑热息痛达1年或更长时间的女性的优势比(OR)分别为0.77(95%置信区间(95%CI):0.62, 0.95)和0.76(95%CI:0.65, 0.88)。每日剂量的阿司匹林(75毫克)和扑热息痛(高达2000毫克)显示出最大程度的风险降低。使用非阿司匹林非甾体抗炎药超过1年与乳腺癌风险降低无关(OR = 1.00(95%CI:0.84, 1.17)),在使用时间至少为2年的使用者中的相应估计值相似。我们的研究结果表明,心脏预防剂量的阿司匹林以及镇痛剂量的扑热息痛与乳腺癌风险降低相关。